Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,554.00p

Change Today:

-90.00p
52 Week High: 12,940.00
52 Week Low: 9,667.00

Currency: UK Pounds
Shares Issued: 1,550.70m
Volume: 1,371,011

Market Cap: £194,675m
RiskGrade: 123
Beta: 0.01

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart (16-10-2025)

6 Month Chart

More AstraZeneca charts

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

	Latest	F'cast
Div Yield	1.8%	0.0%
Div Cover	2.6	2.8
Op Mrgn	18.5%	31.8%
ROCE	60.7%

	Latest	F'cast
P/E	20.5	18.6
PEG	1.6	1.8
Pr/Revenue	4.8	3.4
Pr/Book	6.4

	Latest	F'cast
Revenue	18.0%	-20.0%
PBT	26.0%	58.4%
EPS	13.1%	10.3%
DPS	6.9%	-41.8%

AstraZeneca Fundamentals

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	26,617.00	3,916.00	244.00¢	40.3	0.3	+137%	280.00¢	2.8%
31-Dec-21	37,417.00	(265.00)	8.00¢	1,458.0	n/a	-97%	287.00¢	2.5%
31-Dec-22	44,351.00	2,501.00	212.00¢	71.1	0.0	+2,550%	290.00¢	1.9%
31-Dec-23	45,811.00	6,899.00	726.00¢	19.6	0.1	+242%	290.00¢	2.0%
31-Dec-24	54,073.00	8,691.00	821.00¢	17.1	1.3	+13%	310.00¢	2.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-25	58,175.14	18,507.22	678.61p	18.5	1.8	+10%	242.39p	0.0%
31-Dec-26	61,684.26	20,663.63	770.43p	16.3	1.2	+14%	255.20p	0.0%
31-Dec-27	65,210.30	22,733.90	854.23p	14.7	1.4	+11%	267.16p	0.0%

AstraZeneca forecasts

AstraZeneca Company Announcements

Agreement with US Govt to lower medicine prices	13-Oct-2025	07:00	RNS
Baxdrostat met primary endpoint in Bax24 Ph3 trial	07-Oct-2025	07:00	RNS
Datroway improved OS and PFS in TROPION-Breast02	06-Oct-2025	07:30	RNS

More astrazeneca company announcements

AstraZeneca ShareCast News

Deutsche Bank downgrades AstraZeneca to 'sell'	16-Oct-2025	ShareCast
AstraZeneca to cut US drug prices in key White H...	13-Oct-2025	ShareCast
AstraZeneca's Baxdrostat hits Phase III endpoint...	07-Oct-2025	ShareCast

More AstraZeneca ShareCast news

AstraZeneca Top Newspaper Links

Fighting Frenchman shows us how as he ensures As...	30-Dec-2014	Daily Mail
Exclusive: UK firms vie for share of £170bn in A...	08-Dec-2014	The Independent
MARKET REPORT: Ariad on the up amid growing spec...	04-Dec-2014	Daily Mail

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

AstraZeneca Market Data

Currency	UK Pounds
Share Price	12,554.00p
Change Today	-90.00p
% Change	-0.71 %
52 Week High	12,940.00
52 Week Low	9,667.00
Volume	1,371,011
Shares Issued	1,550.70m
Market Cap	£194,675m
Beta	0.01
RiskGrade	123